Before revision:  Our model is trained and evaluated on two SARS-CoV-2 drug combination screens and achieves 0.777 test AUC , which is 10\% higher than the model trained without drug-target interaction  .
After revision:  Our model is trained and evaluated on two SARS-CoV-2 drug combination screens and achieves 0.777 test AUC , which is 10\% higher than the model trained without drug-target interaction how a biological target affects drug synergy. By utilizing additional biological information, our model achieves 0.78 test AUC in drug synergy prediction using only 90 COVID drug combinations for training. We experimentally tested the model predictions in the U.S. National Center for Advancing Translational Sciences (NCATS) facilities and discovered two novel drug combinations (Remdesivir + Reserpine and Remdesivir + IQ-1S) with strong synergy in vitro .